ProPhase Labs, Inc. Common Stock (DE) (PRPH)
ProPhase Labs, Inc. is a healthcare company primarily involved in the development, manufacturing, and marketing of wellness, diagnostic, and other healthcare products. Founded in 1986, the company has a diverse portfolio that includes dietary supplements, over-the-counter drugs, and diagnostic testing services, with a focus on innovative solutions to improve health and wellness.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 3, 2022 | $0.30 | 2022-05-24 | 2022-05-25 |
| March 10, 2022 | $0.30 | 2022-02-28 | 2022-03-01 |
| June 3, 2021 | $0.30 | 2021-05-24 | 2021-05-25 |
| December 12, 2019 | $0.25 | 2019-12-02 | 2019-12-03 |
| January 24, 2019 | $0.25 | 2019-01-09 | 2019-01-10 |
Dividends Summary
- ProPhase Labs, Inc. Common Stock (DE) has issued 6 dividend payments over the past 4 years
- The most recent dividend was paid 1205 days ago, on June 3, 2022
- The highest dividend payed out to investors during this period was $1 per share
- The average dividend paid during this period was $0.40 per share.
Company News
ProPhase Labs reported a Q2 2025 revenue of $1.2 million, missing analyst expectations, but narrowed its GAAP loss to $(0.11) per share. The company is focusing on cost reduction, potential insurance receivables recovery, and exploring a sale of its Nebula Genomics division.
ProPhase Labs announced the formation of a Clinical Science Advisory Board to support the commercialization of its BE-Smart molecular test for esophageal disease. The advisory board includes experts in the field and aims to accelerate the regulatory and commercialization pathway for the test.
In our monthly Rare Stock Picks series, we're highlighting May 2024 investment picks. Click here for the list of May 2024 Buy recommendations.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 10.91% and 9.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Over the past 3 months, 4 analysts have published their opinion on ProPhase Labs (NASDAQ:PRPH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, ProPhase Labs has an average price target of $14.75 with a high of $15.00 and a low of $14.00. Below is a summary of how these 4 analysts rated ProPhase Labs over the past 3 months. The greater the number of bullish ...Full story available on Benzinga.com